CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE

Provided is a method for using a STAT3 inhibitor having a high antitumor effect and little side effects. The antitumor agent comprises a combination of a quinoline carboxamide derivative of formula (I) below or a pharmacologically acceptable salt thereof with one or more cancer molecular target drug...

Full description

Saved in:
Bibliographic Details
Main Authors YOSHINAGA, Akiko, TSUGANE, Momomi, IIJIMA, Takahiro, KONISHI, Hiroaki, TAKAHASHI, Hiroyuki, ASAI, Akira
Format Patent
LanguageEnglish
French
German
Published 13.07.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Provided is a method for using a STAT3 inhibitor having a high antitumor effect and little side effects. The antitumor agent comprises a combination of a quinoline carboxamide derivative of formula (I) below or a pharmacologically acceptable salt thereof with one or more cancer molecular target drugs selected from the group consisting of an ALK inhibitor, an EGFR inhibitor, a multi kinase inhibitor, a HER2/EGFR inhibitor, an mTOR inhibitor, a BRAF inhibitor, a MEK inhibitor and a BCR-ABL inhibitor, wherein R1, R2, R3, R4, R5 and R6 are the same or different, and each represent a hydrogen atom, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, COOR7 (wherein R7 represents a substituted or unsubstituted alkyl group), or OR8 (wherein R8 represents a substituted or unsubstituted alkyl group).
Bibliography:Application Number: EP20190863743